Dear Kite: With 2300% up­side, we blazed an amaz­ing trail

With the $12 bil­lion Kite buy­out now signed, sealed and de­liv­ered, CEO Arie Bellde­grun has penned a thank-you note to every­one who helped along the way.

Here it is, in its en­tire­ty.


To My Kite Fam­i­ly –

Arie Bellde­grun

For all of us, the Kite ex­pe­ri­ence has been more than just an in­vest­ment op­por­tu­ni­ty or a step­ping stone in a pro­fes­sion­al ca­reer. Over the past eight years, Kite has be­come an in­te­gral part of our lives and a foun­da­tion from which hope be­came more than just an as­pi­ra­tion.

To our pa­tients: You put your faith in us and an ex­per­i­men­tal tech­nol­o­gy known as CAR T ther­a­py. That faith al­lowed a small proof-of-con­cept tri­al to po­ten­tial­ly pro­duce the first-and-on­ly ap­proved CAR T ther­a­py for mul­ti­ple forms of large B-cell lym­phoma. We now have the po­ten­tial to treat thou­sands of pa­tients in need and the means to ex­pand the tech­nol­o­gy to treat many oth­er tu­mors.

To clin­i­cians, our stead­fast part­ners: Your tire­less ef­forts in con­duct­ing clin­i­cal tri­als, with the sole pur­pose of giv­ing your pa­tients hope when no oth­er op­tions re­mained, is to be com­mend­ed. You should be proud. Your de­ter­mi­na­tion and ex­per­tise have paved the way for oth­ers to fol­low.

To our in­vestors: I am hon­ored and hum­bled by your con­tin­ued be­lief in us. Some of you joined me in the nascent stages of Kite, where you in­vest­ed in sim­ply my word, pas­sion and be­lief. While oth­er in­vestors came lat­er, all of you stood by our side, time and time again, even when oth­ers tried to in­fuse doubt. You have been wise ad­vi­sors and fierce sen­tinels.

To our Board of Di­rec­tors: Your sup­port and guid­ance is be­yond what any­one may read in an SEC fil­ing. You have been our guardians and teach­ers, each bring­ing your own set of ex­pe­ri­ences and in­sights for the bet­ter­ment of every­one in­volved in Kite. You have helped us build and pre­serve a bright fu­ture for cell ther­a­py.

To our UCLA friends and Sci­en­tif­ic Founders: Back in 2009, your un­pop­u­lar be­lief that cel­lu­lar im­munother­a­py not on­ly held great promise for the treat­ment of pa­tients but could al­so be brought to pa­tients with oth­er­wise in­cur­able can­cer was para­mount to the suc­cess of Kite. Your friend­ship, ex­per­tise and sup­port of the en­tire Kite fam­i­ly for the past eight years is the ul­ti­mate ex­am­ple of a suc­cess­ful aca­d­e­m­ic-in­dus­try part­ner­ship. I can­not thank you enough for all you have done for Kite.

To our em­ploy­ees: I can’t imag­ine work­ing along­side a braver, more pas­sion­ate or more com­mit­ted group of peo­ple, of­ten­times at the qui­et sac­ri­fice of your per­son­al lives. Your de­vo­tion has been with­out lim­it or ques­tion, even in the face of skep­tics.

In a span of just a few short years, we grew from few­er than 10 em­ploy­ees to al­most 700. The com­pa­ny’s val­ue in­creased 2300% from the time of our IPO to near­ly $12 bil­lion with the ac­qui­si­tion by Gilead Sci­ences. Our clos­ing $180 per share price rep­re­sents not just a 960% ap­pre­ci­a­tion from the IPO price of $17 per share, but the largest ever pre-com­mer­cial bio­phar­ma ac­qui­si­tion.

Kite has changed so many lives in just eight years. I know it has changed mine. I hope it has changed yours, too.

In this, my last of­fi­cial up­date as Pres­i­dent and CEO of Kite, I re­main filled with hope. Hope that Kite’s maid­en flight is mere­ly the first leg of a jour­ney, with an ul­ti­mate des­ti­na­tion more amaz­ing than any of us can to­day con­ceive. Hope that we, in­di­vid­u­al­ly, and col­lec­tive­ly, re­main fo­cused on the cure and con­tin­ue to work to­ward this no­ble pur­suit. And, hope that I get the chance to shake your hand and per­son­al­ly thank each of you for what you have done to make the Kite dream pos­si­ble.

Hope is on­ly the be­gin­ning, not the strat­e­gy.

Thank you all again for your years of sup­port. None of this would have been pos­si­ble with­out each of you.

Arie

Com­mu­ni­cat­ing the val­ue of pre­ci­sion med­i­cine

By Natasha Cowan, Content Marketing Manager at Blue Latitude Health.
Many stakeholders are confused by novel precision medicines, including patients and healthcare professionals. So, how can industry help them to navigate this complexity?

Precision medicine represents a new paradigm in healthcare. It embodies the shift from treating many patients with the same therapy, to having the tools to identify the best treatment for every patient.

(Image: Associated Press)

Amarin emerges from an ex­pert pan­el re­view with a clear en­dorse­ment for Vas­cepa and high odds of suc­cess when the FDA weighs in for­mal­ly

Several FDA experts who gathered Thursday to consider the landmark approval of Vascepa to reduce cardio events in an at-risk population voiced their unease about various aspects of the efficacy and safety data, or ultimately the population it should be used to treat. But the overwhelming belief that the data pointed to the drug’s benefit and clearly outweighed risks carried the day for Amarin.

The panel voted unanimously (16 to 0) to support the company’s positive data presentation — backing an OK for expanding the label to include reducing cardio risk. The vote points Amarin $AMRN down a short path to a formal decision by the FDA, with the odds heavily in its favor. Chances are the rest of the questions about the future of this drug will be hashed out in the label’s small print.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 65,500+ biopharma pros reading Endpoints daily — and it's free.

What does $62B buy you these days? A lot, says Take­da ex­ecs as the phar­ma play­er promis­es a block­buster R&D fu­ture

First comes the $62 billion buyout. Then comes the asset auction and reorganization to pay down debt. Now comes the detailed pledge of a bigger, brighter future in drug development.

That’s where Takeda finds itself on R&D day today, about 11 months after closing on their Shire acquisition. R&D chief Andy Plump is joining CEO Christophe Weber and other top members of the team to outline a new set of priorities in the greatly expanded pipeline at Takeda, which has jumped into the top ranks of the world’s pharma giants in the wake of the Shire deal.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 65,500+ biopharma pros reading Endpoints daily — and it's free.

BeiGene CEO John Oyler at an Endpoints event in Shanghai, October 2018 (Credit: Endpoints News/PharmCube)

UP­DAT­ED: Chi­na's BeiGene scores first-ever FDA ap­proval — but can they carve up J&J's block­buster fran­chise?

Weeks after Amgen took a $2.7 billion stake in BeiGene, the Beijing-based biotech has secured its first-ever FDA approval for zanubrutinib, a BTK inhibitor, months ahead of schedule.

BeiGene’s drug, branded as Brukinsa, has secured accelerated approval for adult patients with mantle cell lymphoma (MCL) — a typically aggressive, rare, form of blood cancer — who have received at least one prior therapy.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 65,500+ biopharma pros reading Endpoints daily — and it's free.

Spe­cial re­port: Twen­ty ex­tra­or­di­nary women in bio­phar­ma R&D who worked their way to the top

What differentiates a woman leader in biopharma R&D from a man?

Not much, except there are fewer of them in senior posts. Data suggest women are not more risk-averse, family-oriented or less confident than their male counterparts — indeed the differences between the two sexes are negligible. But a glance at the top R&D positions in Big Pharma leaves little doubt that upward migration in the executive ranks of biopharma R&D is tough.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 65,500+ biopharma pros reading Endpoints daily — and it's free.

GSK's asth­ma bi­o­log­ic Nu­cala scores in rare blood dis­or­der study

GlaxoSmithKline’s asthma drug Nucala, which received a resounding FDA rejection for use in chronic obstructive pulmonary disease (COPD) last year, has shown promise in a rare blood disorder.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 65,500+ biopharma pros reading Endpoints daily — and it's free.

Mer­ck buys a fledg­ling neu­rode­gen­er­a­tive biotech spawned by an old GSK dis­cov­ery al­liance. What’s up with that?

Avalon Ventures chief Jay Lichter has a well-known yen for drug development programs picked up in academia. And what he found in Haoxing Xu’s lab at the University of Michigan pricked his interest enough to launch one of his umbrella biotechs in San Diego.

Xu’s work laid the foundation for Avalon to launch Calporta, which has been working on finding small molecule agonists of TRPML1 (transient receptor potential cation channel, mucolipin subfamily, member 1) for lysosomal storage disorders. And that pathway, they believe, points to new approaches on major market neurodegenerative diseases like Parkinson’s, ALS and Alzheimer’s.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 65,500+ biopharma pros reading Endpoints daily — and it's free.

Carson Block. Muddy Waters via YouTube

Shorts ga­lore: Mud­dy Wa­ters sees slide for Pep­tiDream, tweets con­cerns about Fi­bro­Gen's new da­ta

The short seller Muddy Waters is taking aim at Japan’s most profitable biotech, projecting a slide for a company that has skyrocketed over the last four years. Meanwhile, the firm tweeted out an analysis accusing FibroGen of manipulating data to obscure safety concerns in their latest reveal, although some investors seem satisfied by the biotech’s explanation.

Muddy Waters shorted PeptiDream, a Japanese biotech-for-hire that leveraged its peptide library into partnerships with some of the world’s largest pharmaceutical companies, a 50% profit margin and $6 billion valuation. The firm noted that despite its esteem, PeptiDream has failed to bring a drug to market 13 years after its 2006 launch (although this is not especially rare for biotech).

Pin­cer move­ment: Cal­i­for­nia biotech gets $35M to suf­fo­cate can­cer in co­or­di­nat­ed at­tack

Having served in Afghanistan, the navy veteran leading California-based EpicentRx wants to leave no patient behind with his arsenal of anti-cancer drugs. On Thursday, the company was given a $35 million boost to further its mission.

The injection of funds will be used to shepherd its late-stage CD47 drug, RRx-001, to the FDA for marketing, and its oncolytic virus program into the clinic.

RRx-001, engineered as an agent that makes tumor cells more sensitive to therapy, is in a Phase III trial in combination with chemotherapy for use in third-line and beyond small cell lung cancer (SCLC). The drug has been granted orphan drug designation from FDA for SCLC, neuroendocrine cancer and glioblastoma.